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ABSTRACT Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria men-
ingitidis serogroup B (NmB) disease, was licensed for use in adolescents and young
adults after it was demonstrated that it elicits antibodies that initiate complement-
mediated killing of invasive NmB isolates in a serum bactericidal assay with human
complement (hSBA). The vaccine consists of two factor H binding proteins (fHBPs)
representing divergent subfamilies to ensure broad coverage. Although it is the sur-
rogate of efficacy, an hSBA is not suitable for testing large numbers of strains in lo-
cal laboratories. Previously, an association between the in vitro fHBP surface expres-
sion level and the susceptibility of NmB isolates to killing was observed. Therefore, a
flow cytometric meningococcal antigen surface expression (MEASURE) assay was de-
veloped and validated by using an antibody that binds to all fHBP variants from
both fHBP subfamilies and accurately quantitates the level of fHBP expressed on the
cell surface of NmB isolates with mean fluorescence intensity as the readout. Two
collections of invasive NmB isolates (n  1,814, n  109) were evaluated in the as-
say, with the smaller set also tested in hSBAs using individual and pooled human se-
rum samples from young adults vaccinated with bivalent rLP2086. From these data,
an analysis based on fHBP variant prevalence in the larger 1,814-isolate set showed
that 91% of all meningococcal serogroup B isolates expressed sufficient levels of
fHBP to be susceptible to bactericidal killing by vaccine-induced antibodies.
IMPORTANCE Bivalent rLP2086 (Trumenba) vaccine, composed of two factor H
binding proteins (fHBPs), was recently licensed for the prevention of N. meningitidis
serogroup B (NmB) disease in individuals 10 to 25 years old in the United States.
This study evaluated a large collection of NmB isolates from the United States and
Europe by using a flow cytometric MEASURE assay to quantitate the surface expres-
sion of the vaccine antigen fHBP. We find that expression levels and the proportion
of strains above the level associated with susceptibility in an hSBA are generally
consistent across these geographic regions. Thus, the assay can be used to predict
which NmB isolates are susceptible to killing in the hSBA and therefore is able to
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demonstrate an fHBP vaccine-induced bactericidal response. This work significantly
advances our understanding of the potential for bivalent rLP2086 to provide broad
coverage against diverse invasive-disease-causing NmB isolates.
KEYWORDS meningococcal antigen surface expression (MEASURE) assay, Neisseria
meningitidis serogroup B, factor H binding protein, flow cytometry, vaccine
Neisseria meningitidis can cause devastating invasive disease that often progressesvery rapidly and is therefore difficult to diagnose and treat (1). The burden of
disease is highest in children 1 year old, followed by a second peak during adoles-
cence (2). There are 12 known serogroups of N. meningitidis based on different capsular
polysaccharide structures, of which 6 (A, B, C, W, Y, and X) are most commonly
associated with significant clinical disease (3, 4). Currently, polysaccharide conjugate
vaccines (serogroups A, C, W, and Y) and outer membrane protein antigen vaccines
(serogroup B) are commercially available. Polysaccharide vaccines for disease due to
N. meningitidis serogroup B (NmB) could not be developed because of its similarity to
a human neural antigen (5–7).
The search for an NmB vaccine led to the discovery of the outer membrane lipidated
protein factor H binding protein (fHBP) as a vaccine candidate (8, 9). Binding of human
factor H, a negative regulator of the alternative complement pathway, to fHBP helps the
organism evade host innate immunity (10). fHBP (also known as LP2086) is a 28-kDa
lipoprotein located in the outer membrane of NmB isolates, as well as isolates from
other serogroups (9). The gene for fHBP is present in most of the meningococcal
isolates examined and is an important virulence factor for survival of the bacteria in vivo
(11–14). fHBP can be classified by amino acid sequence into two subfamilies, A and B.
While the sequence similarity within each subfamily is high (83%), the sequence
similarity between the two subfamilies is only 60 to 75% (13). Thus, an effective vaccine
that is based only upon fHBP must contain a lipoprotein antigen from each subfamily
to be broadly protective (15). Recently, two fHBP-based vaccines, Trumenba (bivalent
rLP2086) and Bexsero (4CMenB), the latter of which contains additional antigenic
components, were licensed in the United States for use in 10- to 25-year-olds for the
prevention of invasive NmB disease (16). Licensure was achieved after it was demon-
strated that the vaccines generated antibodies that could kill representative disease-
causing NmB isolates in a serum bactericidal assay with human complement (hSBA)
(17–20).
The hSBA, used to measure individual vaccination response rates, also provides an
indication of protection at the level of the population targeted to receive the vaccine.
The meningococcal polysaccharide conjugate vaccines for N. meningitidis A, C, Y, and
W were licensed on the basis of the SBA as an immunologic surrogate of efficacy using
corresponding capsule-expressing isolates (21). However, the challenge for a noncap-
sular antigen vaccine is in estimating the breadth of immune protection across the
sequence heterogeneity and surface expression variation present among menin-
gococcal isolates. It is necessary to demonstrate that an hSBA response can be
elicited against a large proportion of the NmB isolates in both fHBP subfamilies,
regardless of sequence variation or antigen expression levels. The hSBA is not
practical for testing large numbers of NmB isolates because of the serum volume
required, as well as the considerable challenges in identifying appropriate human
complement sources for each isolate. The pivotal immunogenicity assessment in
clinical studies for the United States licensure of rLP2086 included five coprimary
immunogenicity endpoints to demonstrate that the vaccine induces protective re-
sponses against four strains representing the diversity of fHBP and common circulating
strains. These four isolates were selected in an unbiased fashion from a large collection
of NmB isolates (i.e., a systematically assembled collection of invasive-disease-causing
NmB isolates obtained from the United States, the United Kingdom, France, Norway,
the Czech Republic, Spain, and Germany [n  1,814]) and adjusted on the basis of fHBP
variant prevalence (11, 13, 22). An earlier study demonstrated that in vitro fHBP surface
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expression could predict susceptibility to killing in an hSBA (15). To assess isolate
diversity and help select representative isolates to demonstrate that the vaccine
provides breadth of coverage in hSBAs in clinical studies (23), it was important to
establish a reliable method to enumerate in vitro surface expression of fHBP on NmB
isolates. Therefore, we developed and validated the meningococcal antigen surface
expression (MEASURE) assay that measures the surface expression of fHBP variants on
intact N. meningitidis isolates. The sequence diversity of fHBP made it important to
identify a universal antibody for the MEASURE assay that was cross-reactive to all NmB
isolates and could accurately quantify the amount of surface-expressed fHBP on diverse
meningococcal isolates. With such an antibody identified and characterized, we sought
to assess all of the isolates in the NmB invasive-isolate set in the MEASURE assay to
characterize their surface expression and to investigate whether expression levels could
predict their potential susceptibility to killing in the hSBA. A subset of isolates (n  109)
was further tested in an hSBA using human bivalent rLP2086 immune serum. A
weighted analysis of these hSBA and fHBP expression data was conducted by using the
entire NmB invasive-isolate set (n  1,814) to evaluate the probability that an isolate
could be killed in the hSBA.
RESULTS
Specificity, reactivity, and affinity of the MN86-994-11-1 MAb for fHBP. The
discovery of broadly cross-reacting monoclonal antibody (MAb) MN86-994-11 was a
fortuitous outcome of hybridoma screening aimed at identifying fHBP antigen-specific
antibodies. The antibody was not bactericidal in an hSBA and therefore has no
therapeutic potential (data not shown). However, flow cytometry screening identified
parent MN86-994 as uniquely cross-reactive against 42 diverse NmB isolates (20 from
subfamily A and 22 from subfamily B). After subsequent cloning, the binding specificity
of MAb MN86-994-11-1 for fHBP on intact bacteria in the presence of other surface
components was determined by using invasive NmB isolates expressing vaccine anti-
gens fHBP-A05 and fHBP-B01 (NmB wild type [WT]) and derived laboratory-generated
fHBP null mutants (NmBΔfHBP) (Fig. 1A). This analysis confirmed that MN86-994-11-1 is
highly specific for fHBP as it bound only to NmB WT isolates and not to NmBΔfHBP
isolates. The use of MAb MN86-994-11-1 in the flow cytometry assay provided the
means to detect fHBP on the surface of NmB bacteria across a range of expression
levels, from very high to low (mean fluorescence intensity [MFI] of 11,098 to 739) for
both subfamily A and B strains (Fig. 1B). To further investigate the relationship between
the total bacterial cell expression of fHBP and the amount of fHBP localized on the
bacterial surface, 38 isolates expressing one of nine different fHBP variants (including
the eight most prevalent variants in the NmB invasive-isolate set) from both subfamilies
A and B were tested by the MEASURE assay and fluorescent Western immunoblotting
of cell lysates using polyclonal bivalent A and B rabbit serum samples. Surface expres-
sion of fHBP by NmB isolates expressing variants from either subfamily correlated well
(R2  0.76) with the total fHBP expression determined by quantitative Western immu-
noblot analysis (Fig. 1C). An MFI of 1,000 was equivalent to approximately 30 pg of
fHBP/g of total cell protein. The quantitative Western immunoblot assay signal was
linear, as demonstrated by dilutions of the cell lysate (data not shown).
In general, higher fHBP expression levels were observed for subfamily B isolates than
for subfamily A isolates. To determine whether the higher expression of fHBP observed
on subfamily B isolates could be due to a greater affinity of the MN86-994-11-1
antibody for subfamily B fHBP variants than for subfamily A variants, kinetic experi-
ments were conducted to assess the affinity of MAb MN86-994-11-1 for eight different
recombinant fHBP variants, four from subfamily A and four from subfamily B (Table 1).
Collectively, the fHBP variants representing each subfamily were chosen for the analysis
to represent all six of the major fHBP subgroups (four for A and two for B) (13, 24). The
MAb exhibited high-affinity binding with subnanomolar KD values and similar associ-
ation and dissociation rates determined for all eight fHBP variants tested, regardless of
whether they were from subfamily A or B. These data indicate that differential affinity
fHBP Expression on NmB Isolates ®
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of the MAb for subfamily A and B variants is not a factor in the generally higher surface
expression levels of subfamily B fHBP-expressing isolates observed.
Binding epitope of the MN86-994-11-1 MAb. The binding epitopes of MAb
MN86-994-11-1 on representative fHBP subfamily A and B antigens rP2086-A05 and
rP2086-B01 were identified by hydrogen-deuterium exchange mass spectrometry
(HDX-MS). Residues showing reduced deuterium exchange in the presence of antibody
were mapped onto the three-dimensional structures of the proteins to visualize the
epitopes (Fig. 2). An epitope common to both antigens was located between residues
FIG 1 MAb MN86-994-11-1 is specific for fHBP and correlates with total cellular fHBP expression. (A) Antibody specificity was confirmed
by obtaining positive MN86-994-11 detection with NmB WT isolates (black line) and no detection on corresponding fHBP NmBΔfHBP
isolates (dashed line), similar to the mouse IgG negative control (gray histogram). (B) Three different isolates expressing A22 fHBP variants
and three different isolates expressing B09 fHBP variants were used to measure fHBP surface expression in a flow cytometry assay with
MN86-994-11-1. (C) Correlation of surface expression of fHBP (MFI, log10) as assessed in the MEASURE assay with MN86-994-11-1 antibody
versus total cellular fHBP as quantitated in whole-cell lysates by fluorescent Western immunoblotting with polyclonal bivalent fHBP A and
B rabbit sera. Thirty-eight isolates expressing the following nine different fHBP variants (number of isolates of each variant tested) were
tested: A05 (4), A12 (1), A22 (7), A29 (3), B03 (4), B09 (3), B16 (3), B24 (8), and B44 (5). Log-transformed data with R2 values are shown. Linear
regression analysis was used to estimate levels of fHBP equivalent to respective MFIs.
TABLE 1 MAb MN86-994-11 binds with high affinity (subnanomolar KD) to both




KD (M) kon (1/Ms) koff (1/s)
A05 (100) 2.29E-11 (1E-12) 3.02E5 (2.77E2) 6.92E-6 (6.52E-8)
A12 (85) 1.73E-11 (1E-12) 4.09E5 (1.27E3) 7.06E-6 (1.94E-7)
A22 (89) 8.64E-11 (1E-12) 2.07E5 (2.22E2) 1.79E-5 (9.02E-8)
A29 (93) 7.36E-11 (1E-12) 2.22E5 (3.51E2) 1.63E-6 (1.37E-7)
B01 (100) 5.73E-11 (1E-12) 3.12E5 (2.28E2) 1.79E-5 (6.77E-8)
B09 (88) 1.25E-11 (1E-12) 2.30E5 (2.86E2) 2.88E-6 (1.08E-7)
B24 (87) 2.58E-11 (1E-12) 2.57E5 (3.30E2) 6.62E-6 (8.89E-8)
B44 (91) 1.50E-10 (1E-12) 8.28E5 (4.76E3) 1.24E-4 (5.95E-7)
aThe affinity of MN86-994-11-1 for fHBP was determined with the Octet RED96 system. Four nonlipidated
recombinant subfamily A variants (A05, A12, A22, and A29) and four nonlipidated subfamily B variants (B01,
B09, B24, and B44) were tested. The percent amino acid sequence identities of fHBP variants to vaccine
antigens A05 and B01 are indicated.
McNeil et al. ®
March/April 2018 Volume 9 Issue 2 e00036-18 mbio.asm.org 4
 on F
ebruary 21, 2020 at B
iblioteca N
acional de C









180 and 194, which corresponds to -strand 11 of the C-terminal -barrel domain and
the loop connecting -strands 11 and 12. For rP2086-A05, the binding site extends
through residue 198 of -strand 12. The difference could be due to the slightly different
proteolytic digest maps of the two proteins. Therefore, it is reasonable to suggest that
since the binding interfaces for both antigens are similar, and given the high specificity
and affinity of the antigen-antibody interactions, -strand 12 may also be part of the
MAb MN86-994-11-1 epitope for rP2086-B01. We propose that the primary binding site
on both proteins is most likely a discontinuous C-terminal domain epitope spanning
residues 180 to 198 on -strands 11 and 12. The amino acid sequence conservation of
this 15-amino-acid binding fragment among all of the fHBP variants present in the
1,814-strain collection was 74% identity and 89% similarity. Flow cytometry showed
that isolates representing all of these sequence variants were readily detected by MAb
MN86-994-11 binding to fHBP on the bacterial surface (Fig. 3).
For rP2086-A05, additional sequences beyond the common epitope also showed
reduced deuterium exchange, including C-terminal residues 166 to 171 of domain
-strand 10 (immediately adjacent to the epitope) and N-terminal domain residues 99
to 108. We hypothesize that this broader binding footprint might be a consequence of
greater flexibility of the rP2086-A05 tertiary structure compared with rP2086-B01,
particularly with regard to interactions between the N- and C-terminal domains.
Consistent with this notion, differential scanning calorimetry experiments show that
the N-terminal domain of fHBP-A05 unfolds at a substantially lower temperature than
that of fHBP-B01 (30.0°C compared to 55.7°C) (see Fig. S2 in the supplemental material).
In addition, residues 97 to 113 of the fHBP-B01 N-terminal domain showed no deute-
rium exchange at all in the absence of antibody compared with the homologous
fHBP-A05 segment, which appears to exchange deuterium freely and make contact
with the antibody (Fig. S3). These studies support the conclusion that the MN86-994-
11-1 primary binding site common to both subfamilies is a conserved conformational
epitope in the C-terminal domain of fHBP.
FIG 2 Mapping of the MN86-994-11 binding epitope on fHBP (rP2086) structural models. A schematic
depiction of the binding residues of MN86-994-11-1 on fHBP is shown. A, rP2086-A05; B, rP2086-B01.
Positions of the segments showing a decrease in deuterium accumulation in the presence of antibody
MN86-994-11 are shown in yellow with the first and last residues of each segment highlighted.
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HDX-MS identification of the MN86-994-11 epitope was confirmed through the
design of a series of mutants with amino acid substitutions within the predicted
binding site. A total of 11 residues that can form hydrogen bonds or salt bridges can
be found between residues 180 and 198. According to the published nuclear magnetic
resonance structure (25), only residues 184 to 198 would form a continuous surface.
Side chains of two residues within that stretch (H188 and E193) point away from the
putative binding interface, which leaves residues K185, D187, K190, S191, N195, and
D197 as potentially involved in MN86-994-11 binding. These six residues were mutated
to alanine, and the ability of the mutant proteins obtained to interact with the antibody
was assessed by isothermal titration calorimetry (ITC). The results are shown in Table 2.
Alanine substitutions at residues K190, S191, and N195 resulted in significant (10-fold)
loss of fHBP-B01 binding affinity for MN86-994-11, indicating that these residues are
directly involved in the interaction. It should be noted that the decrease in binding
affinity is not due to large-scale structural disruption. All six proteins maintain well-
folded secondary and tertiary structures, as evidenced by the well-defined far- and
near-UV circular dichroism (CD) spectra, respectively (Fig. S4). Furthermore, the CD
spectra of the mutant proteins are very similar to those of the corresponding wild-type
protein, indicating that the mutations had little to no effect on protein structure. Taken
together, the ITC data obtained confirm that HDX-MS identification of the MN86-994-11
epitope was correct; the antibody binds primarily to the tip of the loop connecting
-strands 3 and 4 of the C-terminal -barrel domain of the protein.
FIG 3 The MAb MN86-994-11-1 binding epitope is conserved among subfamily A and B fHBP variants
present in the strain pool (n  1,814). Peptide sequences of the MN86-994-11-1 K180-to-L198 binding
site in subfamily A and B antigens defined by deuterium exchange mapping (Fig. 2) are compared. The
number of variants represented by each sequence is indicated along with the mean MFI for each variant
example and its corresponding frequency in the strain pool. An fHBP-B01 isolate (asterisk) is absent from
the collection, but the epitope (shared with fHBP-B44) is included to permit comparisons with other fHBP
variants for MAb MN86-994-11 binding affinity (see Table 1).
TABLE 2 Thermodynamic parameters of the interaction of MN86-994-11 with rP2086-B01
epitope mutantsa
Mutation Ka (M1) Kd (nM) H (kcal/mol) S ([cal/mol] deg1)
None (wild type) (1.8  0.2)  108 6 11.9  0.0 2.2
K185A (0.9  0.1)  108 11 10.8  0.1 0.3
E187A (1.2  0.2)  108 8 10.7  0.1 1.0
K190A (5.9  0.4)  105 1,700 9.3  0.2 4.9
S191A (1.1  0.2)  107 89 8.6  0.1 3.5
N195A (4.7  0.4)  105 2,100 8.9  0.3 3.8
D197A (6.9  1.5)  107 14 12.4  0.1 5.9
aAlanine substitution mutations were introduced into conserved amino acid residues located within the
epitope predicted by HDX-MS mapping (Fig. 2 and 3). Residues were targeted on the basis of their
orientation and potential for forming hydrogen bonds or salt bridges with the antibody. The parameters
were derived from the ITC titrations of the antibody with the wild-type and mutant proteins, as described
in the text. Data are from single experiments with each protein. The errors shown are errors of fit.
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MEASURE assay validation. The MEASURE assay assesses the surface expression of
fHBP on intact fixed bacteria by flow cytometry using broadly cross-reactive MAb
MN86-994-11-1 at a concentration that demonstrated saturation across variants from
subfamilies A and B (6.7 g/ml; Table S2). As shown above, this MAb binds to a
conserved epitope of fHBP variants from both subfamilies and therefore can be used to
quantify the level of fHBP surface expression on N. meningitidis. Whole intact bacteria
are used so that the assay measures the antigen in its native configuration on the cell
surface as it is displayed to the immune system. NmB isolates were grown under the
same culture conditions used to prepare isolates for the hSBA. fHBP surface expression
was subsequently evaluated by flow cytometry by a three-step staining method to
amplify the fluorescence signal and increase the dynamic range of the assay. The MFIs
determined in the assay were then used to compare and rank order isolates by fHBP
surface expression level.
The MEASURE assay was validated to establish its suitability for reliably determining
fHBP surface expression. Specificity and precision (repeatability and intermediate pre-
cision) were examined. Repeatability measures assay variability within an assay run,
whereas intermediate precision measures assay variability over time within a laboratory
while taking into account relevant sources of variation in the operating conditions (e.g.,
different analysts, assay days, etc.). A panel of seven meningococcal isolates was tested
in the MEASURE assay to confirm repeatability and intermediate precision. These
isolates cover a wide range of fHBP surface expression levels (from low to high),
encompass fHBP variants from both subfamilies, and include seven sequence variants
with different N- and C-terminal domains (Table S3). Precision measurements were
conducted on 8 days over 4 weeks by three analysts. On each experimental day, each
analyst independently grew (from separate frozen stocks), stained, acquired, and
analyzed duplicates of the seven isolates, yielding a total of 48 determinations for each
isolate. Each assay plate was read twice, once each using two Accuri C6 flow cytometers
to assess variability in the reading process. The total percent relative standard deviation
(RSD) for each of the seven isolates ranged from 13.2 to 29.1% (data not shown). Table 3
summarizes the results of variance component analysis for all of the isolates, which
takes all factors, including day, analyst, cytometer, and replicates, into account. The
percent total RSD for the panel of isolates was 21.2%, less than the 30% upper limit set
as a prospective acceptance criterion in the validation.
fHBP expression in NmB invasive-isolate set. The MEASURE assay was used to
assess the level of fHBP expression of 1,814 isolates in the NmB invasive-disease-
causing isolate set that had been collected by a prospective systematic approach from
the United States, the United Kingdom, France, Norway, Spain, Germany, and the Czech
Republic (13, 26) (Table S1). The gene encoding fHBP was present in all 1,814 isolates.
The fHBP expression profile of all 1,814 isolates was plotted according to serogroup B
capsule expression or subfamily type with results displayed in aggregate and by
geographic region or individual country (Fig. 4 to 5; Fig. S5 and S6). There was a wide
range of fHBP expression levels among the isolates, with 50% of them expressing
levels of fHBP corresponding to MFIs between 2,000 and 9,000. Approximately 95% of
the isolates showed fHBP surface expression levels above the limit of detection (LOD)
of the MEASURE assay, a level defined as at least an MFI of 100 and 3-fold the MFI
observed with the mouse IgG experimental control antibody. Expression of serogroup
TABLE 3 Precision and repeatability of the MEASURE assay
Factor Variance SD % RSD
Day 0.0007 0.0264 6.1
Analyst 0.0011 0.0334 7.7
Cytometers 0.0004 0.0196 4.5
Replicates 0 0 0.0
Residuals 0.0061 0.0782 18.2
Totals 0.0083 0.0912 21.2
fHBP Expression on NmB Isolates ®
March/April 2018 Volume 9 Issue 2 e00036-18 mbio.asm.org 7
 on F
ebruary 21, 2020 at B
iblioteca N
acional de C









B capsule had no impact on the ability to detect fHBP, as the antigen was as readily
detected in isolates expressing the highest levels of capsular polysaccharide as those
expressing lower levels with no discernible trend (Fig. 4A; Fig. S5). Median surface
expression values were determined for the most prevalent fHBP subfamily A and B
sequence variants in the NmB invasive-isolate set (A05, A07, A06, A12, A19, A22, B03,
B09, B16, B24, B44), which account for 76% of the isolates in this collection (Table S4).
Figure 5 shows that while the fHBP expression level distributions in subfamily A were
very similar between isolates collected in the United States and Europe, the subfamily
B expression level distribution tended to be higher in the United States, driven mostly
by the preponderance of B24-expressing isolates (42% of the total) (27, 28), which
generally have high fHBP surface expression levels (Table S4). A substantial proportion
of these B24 United States isolates are from Oregon (104/184; 56.5%) where hyperen-
demic strains are circulating (29). Of the 77 NmB isolates below the assay LOD, 24 were
FIG 4 fHBP expression is detected on 95% of the isolates in the NmB invasive-isolate set (n  1,814).
fHBP surface expression levels of subfamily A (n  550) and B (n  1,264) isolates in the NmB
invasive-isolate set (n  1,814) are shown. (A) Correlation of serogroup B capsular polysaccharide MFIs
(y axis) with the fHBP expression level MFI (x axis) as measured by the broadly cross-reactive fHBP MAb
MN86-994-11-1. Subfamily A isolates are represented by blue squares, and subfamily B isolates are shown
as green diamonds. (B) Isolates were binned on the basis of the level of fHBP expression (MFI) in the
MEASURE assay. The y axis represents the frequency of isolates in each binned group. The background
category includes strains with an MN86-994-11-1 MFI of 3 times the mouse IgG (negative control) MFI
or an MFI of 100.
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United States isolates (24/432; 5.56%) and 53 were European Union isolates (53/1382;
3.84%). In both geographic regions, these isolates represented diverse sequence type
(ST) clonal complexes and showed a similar age distribution (data not shown).
Predicting the probability of NmB isolate susceptibility in the hSBA. While an
hSBA is the only accepted surrogate of meningococcal vaccine efficacy, it was previ-
ously reported that surface expression of fHBP can predict susceptibility to killing of
NmB isolates with fHBP immune serum samples, and a tentative threshold surface
expression level associated with killing was proposed (15). In this more comprehensive
investigation, we evaluated 109 NmB isolates by both MEASURE and an hSBA to
confirm the relationship between the fHBP surface expression level and susceptibility to
hSBA killing and to define a predictive MEASURE assay threshold based on statistical
analysis. Sixty-four of these isolates were selected randomly and represent the genetic
diversity of circulating invasive isolates identified in the prevalence-based strain col-
FIG 5 fHBP expression levels are distributed similarly in European Union (EU) and United States isolates.
fHBP surface expression levels in the United States (n  432) and European Union (n  1,382) subsets
of the prevalence-based collection of invasive NmB isolates (n  1,814) are shown. (A) Subfamily A
isolates from the United States (n  149) and the European Union (n  401). (B) Subfamily B isolates from
the United States (n  283) and the European Union (n  981). Isolates were binned on the basis of their
level of fHBP expression (MFI) in the MEASURE assay. The y axis represents the frequency of isolates in
each binned group. Background denotes an MFI of 3 times the mouse IgG (negative control) MFI
and/or an MFI of 100.
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lection (n  1,814). In addition, some isolates selected from historical collections (n 
45) were also included. Collectively, these 109 isolates represent 12 diverse ST clonal
complexes and expressed 38 different fHBP variants that account for 82.7% of the
variants in the prevalence-based collection. The 22 subfamily A variants in this strain
collection have 85.1% amino acid sequence identity with the variant A05 vaccine
antigen, while the 16 subfamily B variants have 86.2% sequence identity with the
variant B01 vaccine antigen. The levels of fHBP expression produced MFIs of 157 to
64,511, with a median MFI of 2,961.
The activities of pre- and postvaccination serum samples from individual subjects
were compared to a pool of the respective serum samples in hSBAs with 3 fHBP
subfamily A and 3 subfamily B isolates selected from the 109 NmB strains. Results
shown in Fig. 6 demonstrate that similar hSBA titers were obtained with postvaccina-
tion pooled serum samples and individual immune serum samples. This provided
confidence that pooled serum samples could be used instead of individual serum
samples for the testing of larger numbers of strains, thereby avoiding restriction of the
scope of hSBA testing because of limited serum availability. Isolates with higher fHBP
expression levels did not show significantly higher hSBA titers than those with lower
expression levels, suggesting that beyond a certain threshold, isolates may be similarly
susceptible to vaccine immune sera. The baseline hSBA titers of the prevaccination
pooled serum samples were equal to or lower than the prevaccination geometric mean
titers (GMTs) of the individual-subject serum samples comprising the pool. However,
this had little impact on the fold increase over baseline responses (that define re-
sponder rates), as the postvaccination individual-subject serum GMTs were mostly (i.e.,
in four of six cases) slightly higher than the titers obtained with postvaccination pools.
Next, the pre- and postvaccination pooled serum samples were used to determine
the susceptibility to killing in hSBAs by using the remainder of the isolates in the
109-strain set. Collectively, 87 (approximately 80%) of the 109 isolates were killed by
bivalent rLP2086 vaccine-elicited antibodies in postvaccination serum (Fig. 7). A strain
was considered susceptible in an hSBA only if a 4-fold rise in hSBA titer was observed
between the pre- and postimmune human serum samples for 50% of the assays that
met system suitability criteria with different complement lots (see Materials and
Methods). For example, three isolates were killed in two out of five experiments (with
different complement lots) but were not counted as susceptible. The median hSBA titer
FIG 6 GMTs of individual serum samples from a phase 1 study are similar to those of serum pools in hSBAs with NmB isolates that express fHBP
subfamily A or B variants. The susceptibility of subfamily A and B isolates to vaccine immune serum samples was evaluated, and the mean fHBP
surface MFIs were determined by MEASURE assay with MAb MN86-994-11 (mean value of three experiments  the standard deviation).
Preimmune and immune serum samples from five individual subjects were pooled, and the hSBA activities of the pools were compared with those
of individual serum samples (GMTs with 95% confidence intervals).
McNeil et al. ®
March/April 2018 Volume 9 Issue 2 e00036-18 mbio.asm.org 10
 on F
ebruary 21, 2020 at B
iblioteca N
acional de C









obtained for the group of 109 isolates with the pooled prevaccination serum was 2.
Four strains yielded prevaccination hSBA titers of 8, and for these strains, 8- to 61-fold
titer increases were observed in postvaccination serum samples. The median titer
obtained by using the pooled postvaccination serum samples was 153. In hSBAs using
the pooled postimmune serum samples, a titer of at least 8 was obtained for all of the
isolates that were declared susceptible. There was a poor correlation (R2, 0.5) between
the hSBA titer obtained and the level of fHBP detected in the MEASURE assay for strains
expressing either subfamily A or subfamily B fHBPs (Fig. 7A; linear regression analysis of
log-transformed data not shown). In contrast, visual inspection of the rank-ordered MFI
data (Fig. 7B) for the 109 isolates evaluated in the hSBA suggested an MFI breakpoint
of approximately 1,000, above which isolates were predominantly susceptible in an
hSBA and below which a larger proportion of strains were not killed by bivalent
FIG 7 NmB fHBP surface expression level (MFI) and susceptibility to killing in an hSBA by bivalent fHBP immune serum.
fHBP surface expression is determined by the binding of broadly cross-reactive MAb MN86-994-11-1 to NmB isolates in the
MEASURE assay. The 109 NmB isolates were also tested in the hSBA with pooled human pre- and postvaccination bivalent
rLP2086 immune serum samples. (A) For each of the 109 isolates, the postvaccination hSBA titer is plotted versus the level
of fHBP surface expression. In cases where more than one assay was conducted with the same strain, the GMT was used.
The symbol associated with each isolate conveys both the fHBP subfamily expressed and whether or not the isolate is killed
(4-fold increase in titer comparing pre- and postvaccination serum pools) with immune serum samples in an hSBA (B)
Isolates were ordered from high to low fHBP surface expression and separated into killed and not killed groups on the basis
of the 4-fold rise in hSBA titers between pre- and postvaccination serum pools. Green diamonds represent killed isolates,
and red triangles represent isolates that were not killed. The dotted line marks the MFI threshold of 1,000.
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rLP2086 postvaccination immune serum in the hSBA. Exceptions included 10/92 (11%)
isolates above this cutoff that were refractory to bactericidal activity in an hSBA (7
subfamily A and 3 subfamily B isolates) and 5/17 (29%) isolates with fHBP surface
expression levels below this cutoff that were susceptible (4 subfamily A isolates and 1
subfamily B isolate).
The probability that an NmB isolate randomly chosen from among those above a
defined MFI fHBP expression cutoff will be susceptible in an hSBA was quantitatively
determined by using a weighted analysis that adjusted the proportions of killed isolates
for each variant by the prevalence of that variant in the NmB prevalence-based
collection of 1,814 invasive isolates. The probabilities of such an isolate with an MFI
above a threshold surface expression level being susceptible in an hSBA are shown in
Table 4, along with the percentage of isolates within the set that were above the
defined cutoff. According to this analysis, susceptibility in an in vitro hSBA can be
predicted with high reliability for strains expressing fHBP at MFIs of 1,000.
DISCUSSION
fHBP is an important virulence factor for N. meningitidis that protects the bacteria
from the innate immune response by downregulating the alternative complement
pathway (10, 30, 31). While fHBP expression cannot be directly measured in vivo,
patients recovering from NmB infections develop anti-fHBP antibodies during conva-
lescence (32). In addition, anti-fHBP antibodies are acquired with age, presumably
through carriage acquisition, and are found at levels similar to those in patients
recovering from invasive disease (32, 33). These data provide evidence that fHBP is
expressed in vivo in humans during carriage and invasive disease. fHBP expression can
be detected in vitro by the flow cytometric MEASURE assay. NmB isolates are grown in
liquid culture suspension (rather than agar medium) to better mimic the conditions in
the blood during infection. Furthermore, the bacteria are left intact (rather than lysed)
to determine both fHBP surface expression and the accessibility of fHBP to antibodies
in the presence of other surface antigens, including capsular polysaccharide, providing
a context similar to that encountered by the immune system during infection. The
MEASURE assay employs a broadly cross-reactive MAb, MN86-994-11-1, that recognizes
isolates expressing any fHBP variant. Deuterium-hydrogen exchange mapping and
targeted mutagenesis demonstrated that this MAb binds to a conformational epitope
in the C-terminal -barrel domain conserved in fHBP variants from both subfamilies.
The binding of this MAb to homologous structural segments within both subfamilies of
fHBP is essential for the ability of the MEASURE assay to accurately quantitate the level
of fHBP expressed on the cell surface of all NmB isolates, regardless of the subfamily or
variant. In summary, a combination of in vitro binding kinetics, flow cytometry, epitope
mapping, and fHBP sequence data confirms that the MN86-994-11-1 binding site is
conserved among fHBP antigen variants and that it is accessible on the bacterial surface
to the host immune system.
The MEASURE assay was validated and shown to be a specific and reproducible flow
cytometry-based method used to detect the level of fHBP expressed on the bacterial
surface. In a large, prevalence-based collection of invasive NmB isolates (n  1,814)
from national reference laboratories in the United States and Europe, 95.8% of them




with MFI above cutoff
being killed (%)
% of isolates above cutoff
Total Subfamily A Subfamily B
500 87.4 96.9 92 99.1
1,000 91.2 91.4 80.9 96.0
1,100 91.2 90.4 79.5 95.2
1,500 90.3 84.6 73.6 89.4
2,000 95.8 72.8 61.1 77.9
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demonstrated fHBP expression levels greater than the LOD of the assay (i.e., an MFI of
at least 100 and greater than three times the MFI observed when using the negative-
control IgG). Overall, fHBP expression levels range from the LOD to an MFI of 50,000.
The majority of isolates have moderate expression of fHBP (MFIs of 2,000 to 9,000), with
a median value of 3,300, which corresponds to approximately 120 pg of fHBP/g of cell
lysate. NmB isolates expressing fHBP levels that are below the LOD are not associated
with any particular genotype (as assessed by ST); rather, multiple clonal complexes
are represented. Although it was not investigated in this study, previous analysis
indicates that the fHBP expression level may be influenced by the sequence of the fHBP
promoter region (34). Another contributing factor may be the lower stability and
greater flexibility of fHBP subfamily A variants, revealed by hydrogen-deuterium ex-
change mapping and isothermal scanning calorimetry experiments, which may lead to
faster protein degradation and turnover.
Since antibody cross-linking is important for complement deposition and bacterial
killing, sufficient fHBP expression levels are an important indicator of bacterial isolate
susceptibility. To this end, the MEASURE assay was used to characterize the fHBP
expression levels of all available isolates and further of each fHBP variant group. An
isolate with very low fHBP expression may not be susceptible to antibody cross-linking
and subsequent formation of the complement-mediated membrane attack complex
required for killing of the isolate and thus would not be appropriate for use in an hSBA.
In contrast, one could perceive that an isolate with extremely high fHBP expression may
be more easily killed in an hSBA and not truly represent the preponderance of NmB
invasive-disease-causing isolates within each fHBP variant group. In the present anal-
ysis, we demonstrate that isolates expressing fHBP at the low end of the spectrum (MFI
of 1,000 or 30 pg of fHBP/g of cell extract) can still be killed in an hSBA by bivalent
rLP2086 immune serum samples. This is in contrast to the findings of Biagini et al. (34),
who determined that serum samples elicited by the multicomponent 4CMenB vaccine,
which includes a single nonlipidated fHBP antigen, could not kill strains that expressed
135 pg of fHBP/g of cellular extract. This difference could be due to the absence of
a lipidated fHBP in 4CMenB, as lipidated fHBPs present in bivalent rLP2086 vaccine
induce a substantially more potent immune response in preclinical studies than that of
their nonlipidated counterparts (22). It is important to note the two major differences
between the 4CMenB assessment of Biagini et al. and that described here. First, the
4CMenB assessment was done with murine serum samples, not human serum samples,
as the bivalent rLP2086 assessment was, so one cannot relate the former results to
clinical outcomes. Second, the 4CMenB assessment was conducted in SBAs using rabbit
complement (rSBA). The accepted SBA format for predicting vaccine efficacy against
serogroup B meningococci uses human complement, as rabbit complement does not
provide specificity, resulting in higher titers, which may lead to overestimation of the
vaccine’s effect (35, 36); this is contrary to the finding of lower sensitivity with 4CMenB
murine serum in an rSBA than in the studies reported here with human bivalent
rLP2086 serum in an hSBA.
Despite determining that some strains with low levels of fHBP were susceptible to
immune serum in an hSBA, we sought to identify a predictive threshold where most
strains were susceptible. A probability approach was used to estimate whether strains
with specified levels of fHBP would be susceptible in an hSBA to the bactericidal
antibodies elicited by bivalent rLP2086. An MFI of 1,000 (approximately 30 pg/g of
NmB whole-cell extract) appeared to define a natural breakpoint where the majority of
strains with fHBP MFIs of 1,000 were found to be susceptible in an hSBA using serum
obtained from young adults immunized with bivalent rLP2086. Ten of 92 isolates that
expressed fHBP at levels above the selected predictive threshold were defined as
refractory to hSBA killing. These included strains that expressed fHBP variants A05, A12,
A19, A22, A47, B01, and B16. Other isolates expressing most of these fHBP variants can
be reproducibly killed in hSBAs (23), suggesting that the inability of these isolates to be
killed in an hSBA may be due to cell surface factors other than fHBP. Other surface
components implicated in resistance to serum-mediated bactericidal activity include
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sialylated lipopolysaccharides and TspB proteins (37–39). In practice, such interference
may reflect a common challenge in hSBA development, which is the difficulty, for some
isolates, in identifying conditions that can induce killing in the presence of a vaccine-
elicited antibody. Although it is impractical, isolate susceptibility to a vaccine-elicited
antibody in such cases can be assessed in bactericidal assays with homologous
complement (non-heat-killed prevaccination serum samples from the same subject) or
whole blood.
Our statistical analysis predicts that 91% of the isolates in the set of 1,814 invasive
NmB isolates express fHBP at sufficient levels to be susceptible to bactericidal killing by
rLP2086 vaccine-induced antibodies (i.e., MFIs of 1,000 or approximately 30 pg of
fHBP/g of NmB protein). Given that some isolates below the defined fHBP threshold
can still be shown to be susceptible to human postvaccination polyclonal serum in an
hSBA, the MEASURE assay may underestimate the potential NmB isolate coverage by
the vaccine. Overall, this assessment illustrates the potential of this vaccine to provide
broad coverage against diverse invasive-disease-causing NmB isolates.
Bivalent rLP2086 was licensed by demonstrating that it generated antibodies that
could be shown in an hSBA to kill NmB isolates representative of isolates circulating in
the United States and Europe. The MEASURE assay was used to ensure the selection of
representative NmB isolates for use in hSBAs for the clinical studies. Four diverse
epidemiologically relevant NmB isolates that expressed fHBP variants heterologous to
the vaccine variants were selected in an unbiased fashion from the 1,814-invasive-strain
set, adjusted for prevalence, and tested in the hSBA to assess the efficacy and breadth
of isolate coverage. Clinical study endpoints were achieved with these four strains in
hSBAs with serum samples from vaccinated subjects (reviewed in reference 24). Similar
performance in hSBAs has been demonstrated with additional isolates selected to be
representative of fHBP variant groups and for isolates that have recently caused
meningococcal serogroup B outbreaks (23, 40).
The MEASURE assay was developed as a flow cytometric analytic assay to measure
the native surface expression of fHBP variants on meningococci. We find that expres-
sion levels and the proportion of strains above the level associated with susceptibility
in an hSBA are generally consistent across NmB isolates from the United States and
Europe. The assay has been transferred to two national reference laboratories (Public
Health England and the Centers for Disease Control and Prevention [CDC]), and interlabo-
ratory evaluations are planned. Though the assay can be used to predict which NmB
isolates are potentially susceptible in the hSBA to bactericidal activity elicited by
bivalent rLP2086, knowledge of the fHBP expression level for a given strain cannot
predict the percentage of human subjects who demonstrate bactericidal activity fol-
lowing vaccination and thus the efficacy of the vaccine in the general population. Until
vaccination with NmB vaccines is implemented broadly, population level coverage
conferred by them can only be inferred through the use of hSBAs and assessment of
serum samples from individual vaccinees.
MATERIALS AND METHODS
NmB invasive-isolate set and other strains. To form the NmB invasive-isolate set (n  1,814),
invasive NmB isolates were systematically obtained from public health laboratories from 2000 to 2006 in
the United States, the United Kingdom, France, Norway, and the Czech Republic (n  1,263) as described
by Murphy et al., with the addition of isolates from Spain and Germany (n  551) (Table S1) (11, 13). A
45-invasive-strain collection obtained mostly prior to the year 2000 from the United States and Europe
was also used. Sixty-four invasive isolates randomly selected from a 1,263-isolate subset of the 1,814-
invasive-isolate set plus the 45-strain collection composed the 109-strain set used in hSBAs. United States
isolates were obtained from the CDC Active Bacterial Core Surveillance (ABCs) bacterial collection. Strains
lacking the gene coding for fHBP, for use as flow cytometry negative controls, were constructed by
insertional inactivation of the open reading frame as described previously (9).
Growth of NmB isolates. NmB isolates were grown as previously described (41). Briefly, bacteria
were grown to an optical density at 600 nm between 0.50 and 0.55 and subsequently fixed in 1%
(vol/vol) paraformaldehyde (PFA) in 1 phosphate-buffered saline (PBS) for 10 min to 3 h at 4°C. The
fixed bacterial samples were kept on ice until staining.
Generation of MAb MN86-994-11-1. Hybridomas were generated as previously described (41). The
MN86-994-11 antibody was identified from a hybridoma fusion derived from mice vaccinated with
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rLP2086-A05. Parental hybridoma cultures were initially screened for reactivity against homologous
rLP2086 protein from strain PMB1745 (A05 variant), heterologous rLP2086 protein from strain PMB1135
(B01 variant), and whole cells of N. meningitidis strains expressing fHBP variant A05 or B01. Of the 165
reactive parent hybridomas identified from this fusion, culture supernatants from 33% (n  54) showed
cross-reactivity with the heterologous fHBP-B01 antigen or strain. Screening of candidate hybridomas
from 10 other fusions with fHBP variants as immunogens yielded a total of 97 parents showing some level
of cross-reactivity with antigens from both subfamilies A and B. The broadly cross-reactive hybridoma parent
MN86-994 was cloned by single-cell limiting dilution, and the clone isotype was confirmed by Roche IsoStrips
to be IgG2b .
Recombinant antigens. Nonlipidated recombinant fHBP (rP2086) variants were expressed and
purified as previously described (25). Mutations in the MN86-994-11 binding epitope were introduced by
site-directed mutagenesis. In this case, a His-tagged version of rP2086-B01 cloned into plasmid vector
pET30a was used as the mutagenesis template to facilitate the purification of recombinant mutants. A
mutagenesis kit was used in accordance with the manufacturer’s instructions (QuikChange; Agilent),
mutagenic oligonucleotides used in the reaction were designed with the QuikChange Primer Design
Program, and the presence of intended mutations and the absence of secondary mutations were
confirmed by DNA sequencing. Mutant proteins expressed in Escherichia coli BL21(DE3) were purified by
Ni Sepharose affinity chromatography and size exclusion chromatography (GE Healthcare). All CD and ITC
experiments were done with 1 PBS, pH 7.4. Protein and antibody samples were thoroughly dialyzed
against experimental buffer. Concentrations of rP2086-B01 and MN86-994-11 were determined spectro-
photometrically by using extinction coefficients of 0.363 and 1.4 (mg/ml)1 cm1 at 280 nm, respectively.
Light scattering was taken into account as previously described (42).
Affinity measurements. The affinities of multiple rP2086 (fHBP) variants for MN86-994-11-1 were
tested with the Octet RED96 System (FortéBio). Nonlipidated recombinant fHBP variants A05, A62, A29,
A22, B44, B24, B22, and B01 were individually biotinylated in a one-step reaction with an N-hydroxy-
succinimide–PEG4 – biotin kit. These variants were chosen to represent antigens with a high degree of
sequence divergence from the A05 and B01 vaccine antigens. The biotinylated fHBP antigens were
adsorbed to streptavidin biosensors, and MAb MN86-994-11-1 association and dissociation rates were
determined. The protein concentration used was 10 g/ml, and seven 2-fold serial dilutions of the
MN86-994-11-1 MAb, starting at 25 nM, were used. The raw data were collected and analyzed with Octet
Software.
Western immunoblot assay. Cell pellets of meningococcal bacteria were lysed, and the total cell
protein concentration was determined by the Peterson-modified Lowry protein assay (43). Proteins were
separated by SDS-PAGE and then blotted onto nitrocellulose membrane. A standard curve was also
generated with purified recombinant fHBP of each variant loaded onto the gel in the range of 31.25 to
8,000 pg. The blots were blocked with 5% skim milk in 1 PBS and then incubated with rabbit
anti-bivalent fHBP polyclonal antibodies. After being washed, the blots were incubated in secondary
antibody, goat anti-rabbit IgG (HL) Cy5. Imaging was performed with a 633-nm laser with a 670/BP30
band-pass filter. The images were then analyzed with ImageQuant v5.2 software.
Hydrogen-deuterium exchange experiments. The general operational procedures and HDX-MS
apparatus used have been previously described in detail (44–48). Proteolytic digestion, high-performance
liquid chromatographic separation, mass spectrometric analysis, and peptide identification were done
exactly as previously described, with rP2086-A05 or rP2086-B01 protein and MAb Mn86-994-11-1 (49).
The amount of deuterium accumulated was determined from changes in the molecular weights of the
corresponding peptides at various time points as previously described (49).
CD spectroscopy. All CD experiments were done on a Jasco J-810 automated recording spectro-
polarimeter equipped with a Jasco PTC-424S six-position Peltier-type cell holder. Near-UV CD spectra
were recorded at 20°C in 1-cm rectangular quartz cells from 250 to 320 nm at 100 nm/min, a data pitch
of 0.1 nm, and a bandwidth of 3 nm. The protein concentration was 1.0 mg/ml. Five accumulations were
collected and averaged per spectrum. Data were corrected for baseline contributions and smoothed
with the SpectraManager software provided by Jasco. Near-UV CD data are reported as molar
ellipticity, which was calculated with the equation molar  /(10 · l · C), where molar is the molar
ellipticity (millidegrees  square centimeters/decimole),  is the experimentally measured ellipticity in
millidegrees, l is the cell path length in centimeters, and C is the protein molar concentration.
Far-UV CD spectra were recorded from 200 to 260 nm in 1-mm rectangular quartz cells, with other
parameters being identical to the near-UV CD experiments. The protein concentration was 0.33 mg/ml.
Far-UV CD data are reported as mean residue ellipticity, which was calculated with the equation MRE 
(  106.9)/(10 · l · C), where MRE is the mean residue ellipticity (millidegrees  square centimeters/
decimole),  is the experimentally measured ellipticity in millidegrees, l is the cell path length in
centimeters, and C is the protein concentration in milligrams per milliliter.
ITC. ITC experiments were done with a VP-ITC microcalorimeter (Microcal, Northampton, MA) at 25°C.
All samples were centrifuged at 14,000 rpm for at least 10 min and thoroughly degassed. MN86-994-11
antibody solutions (4.1 M) were titrated with 123 to 154 M solutions of individual MnB rP2086-B01
variants. An initial 2-l injection was followed by 7-l injections at 180-s intervals until no heat exchanges
were observed. MN86-994-11 titrations were corrected for the heat of protein dilution by performing
buffer titrations with the same protein solutions under identical conditions and subtracting the results
from the antibody titrations. Data were fitted to the “single class of binding sites” model with VP-ITC data
analysis software provided by Microcal to determine the binding stoichiometry (N), association constant
(Ka), enthalpy change (ΔH), and entropy change (ΔS) upon binding. The dissociation constant (Kd) was
calculated as 1/Ka.
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MEASURE assay. A volume of 50 l of bacteria fixed in 1% PFA–PBS was plated per well of 96-well
U-bottom polystyrene plates, centrifuged, and washed once in 1% (wt/vol) bovine serum albumin in 1
PBS. MAb MN86-994-11-1 or mouse IgG (negative control) was added to the bacterial pellets, which were
resuspended and incubated on ice for 30 min. After two washes, biotinylated goat anti-mouse IgG
(subclasses 1, 2a, 2b, and 3; Jackson ImmunoResearch, Inc.) was added to the cell pellets, which were
resuspended and incubated on ice for 30 min. The cells were washed twice and resuspended in
streptavidin-phycoerythrin (PE; BD Biosciences) and incubated on ice for 30 min. After an additional two
washes, the cell pellets were resuspended in 1% PFA. Twenty thousand events per well were acquired
on an Accuri C6 flow cytometer and analyzed with Accuri CFlow software (see Fig. S1 for the gating
strategy used). The MFI of the PE channel was determined for each sample after gating on bacterial cells
in the logarithmic forward scatter versus side scatter dot plot. For fHBP expression to be considered
above the LOD of the MEASURE assay, MFIs had to be above an arbitrary threshold of at least 100 and
three times that of the control mouse IgG MFI in that assay. Serogroup B capsular expression was
determined by the same staining procedure as previously described, with the exception of the use of an
anti-serogroup B MAb (NIBSC), followed by incubation with biotinylated goat anti-mouse IgM (Southern
Biotech).
hSBA. hSBAs with human serum samples from young adults were performed as previously described
(19, 50, 51). Human serum with no intrinsic detectable bactericidal activity in screening assays was used
as the exogenous complement source. Subject-matched pooled preimmune serum samples were used
to demonstrate that the hSBA titers observed in the pooled postimmune serum samples were the result
of vaccine-induced antibodies. Moreover, depletion experiments were performed to demonstrate the
specificity of the antibodies for fHBP. Briefly, fHBP from the same subfamily competed with the binding
of serum antibodies with antigen expressed on the surface of the bacteria and significantly reduced the
hSBA titers, whereas irrelevant proteins and polysaccharides used as competitors did not (data not
shown). In the study reported here, 45 of the 109 NmB strains were tested with pre- and postimmune
serum samples from five subjects enrolled in young adult clinical study 6108A1-500 (18 to 25 years old)
and 64 NmB strains were tested with pre- and postimmune serum samples from four of the same five
subjects because insufficient serum was available from the fifth subject (20). Strains were tested in hSBAs
with the pooled human serum samples and up to five human serum complement lots. A strain tested in
the hSBA was designated killed if a 4-fold rise in the hSBA titer was observed between the pre- and
postimmune human serum samples in 50% of the assays that met system suitability criteria. This
stringent approach was taken so that strains could be identified that could be used for clinical testing.
In some instances, strains that could be killed by bivalent rLP2086 serum were scored negative as they
could only be killed with specific complement sources. Appropriate system suitability was achieved if the
ratio of the number of surviving bacteria after the bactericidal incubation in the absence of serum
samples (T30) to the number of input bacteria (T0) was 50%. A strain was considered not susceptible
(not killed) in the hSBA if a 4-fold rise in the hSBA titer was not observed in 50% of the assays. As an
example, if the hSBA titer of the preimmune serum pool was 1:4 (or a titer of 2) for a given NmB strain,
then an hSBA titer of 1:8 with the postimmune serum pool would be required to achieve a 4-fold rise;
if such a 4-fold rise was observed for 50% of the assays (e.g., two or three of three assays meeting
system suitability criteria, three or four of four assays meeting system suitability criteria, three to five of
five assays meeting system suitability criteria), a given NmB strain would be considered susceptible
(killed) in the hSBA.
Statistical analysis. For the hSBA strain pool (n  109), the numbers and proportions of strains
below and above possible cutoffs of strains killed in the hSBA were determined. However, because the
strains tested in the hSBA strain pool were not chosen to mimic the proportions of fHBP variants in the
larger, more representative, extended NmB strain pool (n  1,814), a weighted analysis was performed
by adjusting the proportions of killed strains for each variant by the prevalence of that variant in the
extended NmB strain pool. For strains above the cutoff, P(strain killed by hSBA)  iP(strain killed by
hSBA given that strain is variant type i)  P(strain is variant type i). The first factor in each term of this
sum was estimated from the human SBA strain pool (n  109) data. The second factor, the weight, was
estimated from the extended NmB strain pool (n  1,814).
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